Header Logo

Connection

Mohammed Rassool to Kanamycin

Back to Details
This is a "connection" page, showing publications Mohammed Rassool has written about Kanamycin.
Mohammed Rassool
Connection Strength
0,060
Kanamycin
  1. Long-term efficacy and safety of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): extended follow-up of an open-label, multicentre, randomised, non-inferiority trial. Lancet Respir Med. 2024 Dec; 12(12):975-987.
    View in: PubMed
    Score: 0,060
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.